Filana Therapeutics, Inc. Total Liabilities
Filana Therapeutics, Inc. total liabilities. Based on the latest financial reports, Filana Therapeutics, Inc. (FLNA) has total liabilities worth $40.29 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Filana Therapeutics, Inc. fund operations to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Filana Therapeutics, Inc. (2022–2025)
Total liabilities of Filana Therapeutics, Inc. from 2022 to 2025. This chart illustrates how Filana Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Filana Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Filana Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Native Mineral Resources Holdings Ltd
AU:NMR
|
Australia | AU$27.92 Million |
|
AB Electrolux (publ)
ST:ELUX-A
|
Sweden | Skr105.92 Billion |
|
Metagenomi, Inc. Common Stock
NASDAQ:MGX
|
USA | $61.13 Million |
|
Apexindo Pratama Duta Tbk
JK:APEX
|
Indonesia | Rp176.34 Million |
|
Singsongholdin
KO:006880
|
Korea | ₩165.62 Billion |
|
Findi Ltd
AU:FND
|
Australia | AU$256.05 Million |
|
Hamashbir 365 Holdings Ltd
TA:MSBI
|
Israel | ILA1.28 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Filana Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Filana Therapeutics, Inc. balance sheet assets.
Liquidity & Leverage Metrics
Filana Therapeutics, Inc. Total Liabilities Ratios Explained
Filana Therapeutics, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Filana Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Filana Therapeutics, Inc. (2022–2025)
The table below shows the annual total liabilities of Filana Therapeutics, Inc. from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $43.95 Million | +271.56% |
| 2024-12-31 | $11.83 Million | -16.67% |
| 2023-12-31 | $14.20 Million | +94.59% |
| 2022-12-31 | $7.29 Million | -- |
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from… Read more